← Russell 3000 cross-section

NAGE Niagen Bioscience, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$257m
Revenue TTM
$129m
Net income TTM
$16m
Free cash flow
Composite score
Sector rank
#2758

Valuation

P / E
16.1
EV / EBITDA
22.2
EV / sales
2.0
FCF yield
Earnings yield vs 10-yr
1.50pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
12.4%
EBITDA margin
9.0%
ROE
19.4%
ROIC
12.8%
Revenue growth
11.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

As a result of the disposition, revenue attributable to analytical reference standards and services is no longer included in our ongoing operating results following the closing date. This change is expected to further concentrate our revenue mix toward higher-growth, consumer-oriented product offerings and ingredient sales. The following table sets forth our total net sales by reportable segment: Total net sales decreased by $1.3 million and $0.3 million for the three and six months ended June 30, 2026, respectively, as compared to the same periods in 2025. …Niagen Bioscience, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →